Duloxetine 120 mg offers the greatest economic value for treating moderate-to-severe fibromyalgia, followed by pregabalin 450 ...

Modeling study supports an FDA-approved product over off-label amitriptyline ...

The New Bedford Science Cafe will host a discussion on a new FDA-approved fibromyalgia drug from 6 to 8 p.m. Dec. 2 at The Last Round Bar & Grille, 908 Purchase St., New Bedford. Seth Lederman, MD, ...

A novel formulation of the muscle relaxant drug cyclobenzaprine has won FDA approval for treating fibromyalgia, manufacturer Tonix Pharmaceuticals announced on Friday. To be sold as Tonmya, the ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Tonix Pharmaceuticals Holding Corp.'s key value driver is TNX-102 SL for fibromyalgia, with an FDA decision expected in August 2025; approval could spike shares, and rejection could devastate them.

The United States Food and Drug Administration recently approved Tonmya TM (cyclobenzaprine hydrochloride sublingual tablets) ...

Fibromyalgia is characterized by chronic pain from no clear source. Patients with fibromyalgia frequently have sleep problems: Their deep sleep brain wave patterns are often disrupted by brain waves ...

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

Disturbed sleep is a prominent feature of fibromyalgia symptomatology and has been proposed as one of the core symptoms that should be systematically assessed in clinical trials for the treatment of ...